45 completed. 45 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 45 | Completed 45 |
| Phase 2 | 15 | Completed 15 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d - Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization | Phase 1 | Completed | Sylentis, S.A. | 36 | 2021-03-17 | 2022-03-31 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
| Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant - Limbal Stem Cell Deficiency | Phase 1 / Phase 2 | Completed | Massachusetts Eye and Ear Infirmary | 23 | 2016-08-01 | 2025-01-15 |
| Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD OPT-302, Lucentis™ - Eye Diseases, Macular Degeneration | Phase 1 | Completed | Opthea Limited | 51 | 2015-07-01 | 2017-11-06 |
| Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration Aflibercept - Neovascular Macular Degeneration | Phase 1 | Completed | University of Nebraska | 5 | 2014-09-05 | 2023-09-06 |
| A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel - Corneal Neovascularization, Corneal Graft Failure | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 75 | 2014-04-01 | 2020-08-10 |
| Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration CLG561 - Age-related Macular Degeneration | Phase 1 | Completed | Alcon Research | 50 | 2013-05-01 | 2016-03-25 |
| Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome EYLEA (Aflibercept) intravitreal injection - Choroidal Neovascularization, Presumed Ocular Histoplasmosis | Phase 1 | Completed | Retina Research Institute, LLC | 5 | 2012-06-01 | 2018-08-29 |
| Propranolol for Diabetic Retinopathy Propranolol - Proliferative Diabetic Retinopathy | Phase 1 | Completed | University of Wisconsin, Madison | 9 | 2012-02-01 | 2017-03-31 |
| Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration rAAV.sFlt-1, Control (ranibizumab alone) - Macular Degeneration, Age-related Maculopathies | Phase 1 / Phase 2 | Completed | Lions Eye Institute, Perth, Western Australia | 40 | 2011-12-01 | 2017-09-01 |
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 2.0 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2011-09-01 | 2022-12-12 |
| Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) high-dose ranibizumab, ranibizumab - PCV, Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Hawaii Pacific Health | 24 | 2010-11-01 | 2017-10-09 |
| Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration LFG316 - Advanced Age-related Macular Degeneration | Phase 1 | Completed | Novartis Pharmaceuticals | 24 | 2010-11-01 | 2012-05-01 |
| Treatment of Corneal Neovascularization With Topical Pazopanib Pazopanib (5mg/ml) - Corneal Neovascularization | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 20 | 2010-11-01 | 2018-01-18 |
| 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) IBI-20089/Lucentis - Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 1 / Phase 2 | Completed | University of Illinois at Chicago | 10 | 2010-09-01 | 2014-10-20 |
| A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration Pazopanib - Macular Degeneration | Phase 1 | Completed | GlaxoSmithKline | 15 | 2010-08-16 | 2017-11-09 |
| A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans GW786034, Placebo - Macular Degeneration | Phase 1 | Completed | GlaxoSmithKline | 72 | 2010-01-12 | 2017-11-14 |
| Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) AAV2-sFLT01 - Macular Degeneration, Age-Related Maculopathies | Phase 1 | Completed | Genzyme, a Sanofi Company | 19 | 2010-01-11 | 2018-08-22 |
| Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel - Corneal Neovascularization, Corneal Graft Failure | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 30 | 2009-12-01 | 2018-06-15 |
| A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD Intravitreal injection of KH902 - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Chengdu Kanghong Biotech Co., Ltd. | 36 | 2009-08-01 | 2014-03-27 |
Showing 20 of 45. Sign in to see all of them.
Choroidal Neovascularization (28) · Macular Degeneration (23) · Neovascularization, Pathologic (8) · Corneal Neovascularization (7) · Polypoidal Choroidal Vasculopathy (5) · Eye Diseases (4) · Diabetic Retinopathy (3) · Retinal Degeneration (3) · Retinal Diseases (3) · Geographic Atrophy (2) · Inflammation (2) · Macular Edema (2) · Myopia, Degenerative (2) · Retinal Neovascularization (2) · Retinal Vein Occlusion (2)
Pathologic Processes (45) · Pathological Conditions, Signs and Symptoms (45) · Eye Diseases (38) · Neovascularization, Pathologic (37) · Choroid Diseases (30) · Uveal Diseases (30) · Retinal Diseases (24) · Retinal Degeneration (21) · Corneal Diseases (7) · Cardiovascular Diseases (4) · Eye Diseases, Hereditary (4) · Vascular Diseases (4) · Diabetes Complications (3) · Diabetic Angiopathies (3)
Ranibizumab (16) · Bevacizumab (4) · Triamcinolone Acetonide (3) · aflibercept (3) · pazopanib (3) · Carboxymethylcellulose Sodium (2) · Intravitreal Injections (2) · S 3304 (2) · Sodium Chloride (2) · Adrenal Cortex Hormones (1) · Cerebral Angiography (1) · Laser Therapy (1) · Ophthalmic Solutions (1) · PF-04523655 (1) · Propranolol (1)
National Eye Institute (NEI) (6) · Reza Dana, MD (4) · GlaxoSmithKline (3) · Johns Hopkins University (3) · Hawaii Pacific Health (2) · Massachusetts Eye and Ear Infirmary (2) · Shionogi (2) · Southeast Retina Center, Georgia (2) · Alcon Research (1) · Allergan (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Clement K. Chan (1) · Genzyme, a Sanofi Company (1) · Graybug Vision (1) · Lions Eye Institute, Perth, Western Australia (1)
United States (37) · Australia (1) · China (1) · Israel (1) · Italy (1) · Spain (1)
Reza Dana, MD, MPH, MSc (3) · Dennis M. Marcus, M.D. (2) · Quan D Nguyen, MD, MSc (2) · Reza Dana, M.D., MPH (2) · Charles P. Semba, MD (1) · Clement K Chan, M.D. (1) · Diana V Do, MD (1) · Gregg T Kokame, MD (1) · Gregg T Kokame, MD, MMM (1) · Ian Constable, Professor (1) · Jeffrey S Heier, M.D. (1) · Jennifer I Lim, MD (1)
PMID 24113783, PMID 39207600, PMID 17404091, PMID 18054887, PMID 19365012, PMID 19726427, PMID 20609706, PMID 20827138, PMID 21555610, PMID 22967868, PMID 22990319, PMID 23233252, PMID 23316779, PMID 25277305, PMID 25376617, PMID 26431823, PMID 27865764, PMID 28526489, PMID 40038272, PMID 40152603